Hjem › Immunsystem og lidelser › Oregon
Immunsystem og lidelser kliniske forsøg i Oregon
9 studier for Immunsystem og lidelser søger deltagere på steder i Oregon.
Byer i Oregon
Officiel studietekst (engelsk)
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
- Oregon Health & Science University, Portland
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT07192471A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Oregon Health & Science University, Portland
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 18. sep. 2026 · NCT06722235Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Saint Charles Health System, Bend
- Clackamas Radiation Oncology Center, Clackamas
- og 9 flere
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 17. sep. 2026 · NCT04242095A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Oregon Health & Science University, Portland
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 9. sep. 2026 · NCT06948318A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
- Providence Portland Medical Center, Portland
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 28. aug. 2026 · NCT07075185A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
- Inmagene Site 3, Portland
RekruttererFase 2
Alder 18 til 74 · Alle køn · Opdateret 12. aug. 2026 · NCT07037901Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Oregon Health and Science University, Portland
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 7. jul. 2026 · NCT07216443CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Providence Neurological Specialties West, Portland
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 16. apr. 2026 · NCT03328078A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
- Oregon Health and Science University, Portland
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 15. dec. 2025 · NCT06619561Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.